Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACES: Anticoagulation for New-Onset POAF After CABG
NCT04045665Phase 3Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2019
- Primary completion
- Aug 2026
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism at 180 days and Any BARC type 3 or 5 bleeding at 90 days. Started Dec 2019; status: recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04045665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045665.